Despite the approval of Janus kinase inhibitors and novel agents for patients with
myelofibrosis (MF), disease-modifying responses remain limited, and hematopoietic stem …

Advances in understanding the pathogenesis and molecular landscape of myelofibrosis
have occurred over the last decade. Treating physicians now have access to an ever …

The introduction of JAK inhibitors, leading to regulatory approval of ruxolitinib, represents a
major therapeutic advance in myelofibrosis (MF). Most patients experience reduction in …

Allogeneic hematopoietic stem-cell transplantation (HSCT) is, at present, the only potentially
curative therapy for myelofibrosis (MF). Despite many improvements, outcomes of HSCT are …

Hematopoietic cell transplantation (HCT) is the only curative therapeutic modality for
myelofibrosis (MF) at present. The optimal timing of HCT is not known in the presence of …

Moving from indication to transplantation is a critical process in myelofibrosis. Most of
guidelines specifically focus on either myelofibrosis disease or transplant procedure, and …

Abstract Purpose of Review To discuss the current treatment paradigm, review novel targets,
and summarize completed and ongoing clinical trials that may lead to a paradigm shifts in …

Myeloproliferative neoplasm (MPN) is a category in the World Health Organization
classification of myeloid tumors. BCR-ABL1–negative MPN is a subcategory that includes …

Myelofibrosis (MF) is a heterogeneous disorder characterized by splenomegaly,
constitutional symptoms, ineffective hematopoiesis, and an inherent risk of leukemic …

Myelofibrosis (MF) is a heterogeneous disease for which long‐term, effective medical
therapeutic options are currently limited. The role of allogeneic haematopoietic stem cell …